High Grade Astrocytic Tumor

Observed

← altered in cohorts of

ATRNL1

456 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

MYOF

456 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

SEC23IP

456 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

BAG3

455 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CACUL1

455 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

EGFR

455 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

EIF3A

455 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

INPP5F

455 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

MCMBP

455 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PRLHR

455 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

SORBS1

455 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ACTA2

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CTBP2

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CYP26C1

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

DENND10

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

GFRA1

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

GRK5

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

HSPA12A

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

LIPK

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

NANOS1

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PDZD8

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PLPP4

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PNLIPRP1

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PNLIPRP3

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PRDX3

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

RAB11FIP2

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

RGS10

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

SFXN4

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

SLC18A2

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

TBC1D12

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

TIAL1

454 / 601 cases (76 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ABRAXAS2

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ANKRD22

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ATE1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

C10orf82

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CCDC172

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CPXM2

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CYP26A1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CYP2C18

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

DMBT1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

DOCK1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

EMX2

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ENO4

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ENTPD1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

EXOC6

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

FAM204A

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

FAM53B

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

FAS

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

FGFR2

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

HELLS

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

IFIT5

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

KCNK18

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

LHPP

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

LIPF

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

LIPJ

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

LIPM

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

LIPN

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

MKI67

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

NOC3L

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

OAT

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PDE6C

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PDLIM1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PLCE1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PNLIP

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

RNLS

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

SHTN1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

STAMBPL1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

TACC2

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

TLL2

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

VAX1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

WDR11

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ZRANB1

453 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ACADSB

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ATAD1

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

BLNK

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

BTBD16

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

BUB3

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CEP55

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CYP2C8

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

CYP2C9

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

DHX32

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

EDRF1

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

FAM24B

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

FRA10AC1

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

GPR26

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

HMX3

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

IDE

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

IFIT1B

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

IFIT3

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

KLLN

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

LGI1

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

NKX1-2

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

NSMCE4A

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

PKD2L1

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

RBP4

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

SLC35G1

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

TNKS2

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

← altered in cohorts of

ZNF518A

452 / 601 cases (75 %) · ssm · TCGA-GBM

—

Observed

High Grade Astrocytic Tumor investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 172show all (up to 200)
→ investigated in trials for	Temozolomidesmall molecule 306 trials (100 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	306	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 119 trials (20 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	119	Observed	clinicaltrials	graph →
→ investigated in trials for	Lomustinesmall molecule 39 trials (12 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 37 trials (19 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 31 trials (15 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 17 trials (7 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 16 trials (3 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 15 trials (8 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Vorinostatsmall molecule 14 trials (1 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Carmustinesmall molecule 13 trials (1 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 12 trials (3 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 11 trials (0 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Temsirolimussmall molecule 11 trials (0 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Cediranibsmall molecule 10 trials (1 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 8 trials (5 active) · roll-up of the cancer and its descendants	—	—	High Grade Astrocytic Tumor	8	Observed	clinicaltrials	graph →

High Grade Astrocytic Tumor investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 172show all (up to 200)

→ investigated in trials for

Temozolomidesmall molecule

306 trials (100 active) · roll-up of the cancer and its descendants

—

306

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

119 trials (20 active) · roll-up of the cancer and its descendants

—

119

Observed

→ investigated in trials for

Lomustinesmall molecule

39 trials (12 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

37 trials (19 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

31 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

17 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

16 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

15 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vorinostatsmall molecule

14 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carmustinesmall molecule

13 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

12 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

11 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

11 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cediranibsmall molecule

10 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

8 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

High Grade Astrocytic Tumor studied in …STUDIED_INderived10 of 1,778show all (up to 200)
→ studied in	NCT05685004Phase 2/Phase 3 · active not recruiting Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) · condition mapped ALIAS · 1,778 trials mapped (552 active)	—	—	Brain Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05864534Phase 2 · active not recruiting Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05871021Phase 2 · active not recruiting Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05902169Phase 3 · recruiting Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06325683Phase 2 · suspended Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05303467Phase 1 · recruiting A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05432804Phase 1/Phase 2 · recruiting Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma, IDH-Wildtype	1	Observed	clinicaltrials	graph →
→ studied in	NCT07145112Phase 1 · recruiting Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07326566Phase 2 · recruiting Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07416188Phase 1/Phase 2 · recruiting Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →

High Grade Astrocytic Tumor studied in …STUDIED_INderived10 of 1,778show all (up to 200)

→ studied in

NCT05685004Phase 2/Phase 3 · active not recruiting

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) · condition mapped ALIAS · 1,778 trials mapped (552 active)

—

Brain Glioblastoma

Observed

→ studied in

NCT05864534Phase 2 · active not recruiting

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed

→ studied in

NCT05871021Phase 2 · active not recruiting

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed

→ studied in

NCT05902169Phase 3 · recruiting

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed

→ studied in

NCT06325683Phase 2 · suspended

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed

→ studied in

NCT05303467Phase 1 · recruiting

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed

Glioblastoma, IDH-Wildtype

→ studied in

NCT05432804Phase 1/Phase 2 · recruiting

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed

→ studied in

NCT07145112Phase 1 · recruiting

Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed

→ studied in

NCT07326566Phase 2 · recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed

→ studied in

NCT07416188Phase 1/Phase 2 · recruiting

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma · condition mapped CURATED_BROADER · 1,778 trials mapped (552 active)

—

Observed